Analysis of the Clinicopathological Characteristics, Treatment and Prognosis of Unclassifiable B-Cell Lymphoma Intermediated between DLCBL and BL.

De-liang Liu; Biao Wang; Yuan-dong Zhu; Feng Yan

Return

Analysis of the Clinicopathological Characteristics, Treatment and Prognosis of Unclassifiable B-Cell Lymphoma Intermediated between DLCBL and BL.

Author: De-Liang LIU ¹ ; Biao WANG ¹ ; Yuan-Dong ZHU ¹ ; Feng YAN ²
Author Information

1. Department of Hematology,Changzhou First People's Hospital,Changzhou 213003, Jiangsu Province, China.
2. Department of Hematology,Changzhou First People's Hospital,Changzhou 213003, Jiangsu Province, China. E-mail:ysj96227@sina.com.
Publication Type:Journal Article
MeSH: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Prednisone; Prognosis; Retrospective Studies; Vincristine
From: Journal of Experimental Hematology 2018;26(2):443-448
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo analyze the clinicopathological characteristics, treatment and prognosis of patients with unclassifiable B-cell lymphoma intermediated between DLCBL and BL.
METHODSA total of 16 patients with DLBCL/BL in our hospital were included in this study between July 2014 and June 2016. The clinical and pathological data of 16 patients were collected. Kaplan-Meier method was used to estimate and compare overall survival (OS) and progression-free survival (PFS). The log-rank test was used to analyze the influence of age, sex, B symptoms, LDH level, lymyhoma staging, KPS score, Ki-67(%), extranodal sites, IPI score, β2 microglobulin level, DPLs, tumour cell origin and treatment etc. Results: Fifty out of 16 patients showed extra-nodal involvement among the 16 patients with DLBCL/BL. The median OS and PFS times were 11 and 7 months respectively. The one year OS and PFS rates were 50.0% and 43.8% respectively. The borderline difference between the CHOP, CHOP-like, and intensive chemotherapy groups is statistically significant(P=0.067). Univariate analysis showed that IPI score and LDH were significant prognostic factors for the overall survival of the patients with DLBCL/BL.
CONCLUSIONDLBCL/BL is a highly aggressive B-cell lymphoma with a short survival time. DLBCL/BL responded better to intensive chemotherapy than CHOP or CHOP-like regimen. IPI score and LDH level are significant prognostic factors for the overall survival of the patients with DLBCL/BL.